<DOC>
	<DOCNO>NCT02248012</DOCNO>
	<brief_summary>To study efficacy everolimus combine temozolomide first-line treatment advance gastroenteropancreatic neuroendocrine carcinoma Ki67 20-55 % , measure disease control rate ( non-progressive disease ) 6 month .</brief_summary>
	<brief_title>Everolimus Temozolomide Advanced Gastroenteropancreatic Neuroendocrine Carcinoma ( G3 )</brief_title>
	<detailed_description>Guidelines treat advanced gastroenteropancreatic neuroendocrine carcinoma ( GEP-NECs ) advocate use combination chemotherapy platinum-based chemotherapy combine etoposide . No regimen consistently show benefit combination . NECs respond treatment usually apply neuroendocrine tumour somatostatin analogue interferon . In contrast metastatic neuroendocrine tumour low Ki67 , debulking surgery surgery liver metastasis generally recommend . Cisplatin /carboplatin etoposide establish standard treatment advance disease base two small retrospective study show response rate 41- 67 % median survival 15-19 month . In current trial propose alternative treatment subgroup patient GEP-NEC base new data , intention improve response rate clinical benefit rate without increase toxicity</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Inclusion criterion Histologically proven neuroendocrine carcinoma Ki67 2055 % .Primary gastroenteropancreatic tumor cancer unknown primary metastasis mainly abdominalMeasurable disease accord RECIST CT/MR General condition : &gt; 18 year ; WHO/ECOG performance status 01 . Adequate haematological , renal hepatic function : Written inform consent prior inclusion Prior therapy : No prior chemotherapy treatment advance disease . Adjuvant chemotherapy must end &gt; 6 month inclusion . Prior current history : No curatively resectable disease ; No serious illness medical condition ( include : unstable angina , myocardial infarction within 6 month , unstable diabetes , immune suppression ) Concomitant treatment : No concomitant ( within 4 week inclusion ) administration experimental drug ; No concurrent anticancer therapy . Other : Not pregnant breast feeding . Fertile patient must use adequate contraceptive fertile female must negative pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Gastroenteropancreatic</keyword>
	<keyword>Neuroendocrine carcinoma</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>